Department of Pathology, The University of Chicago, Chicago, Illinois.
Department of Health Studies, The University of Chicago, Chicago, Illinois.
Cancer Immunol Res. 2017 Feb;5(2):127-136. doi: 10.1158/2326-6066.CIR-16-0293. Epub 2017 Jan 11.
Adoptively transferred CD8 T cells can stabilize the size of solid tumors over long periods of time by exclusively recognizing antigen cross-presented on tumor stroma. However, these tumors eventually escape T-cell-mediated growth control. The aim of this study was to eradicate such persistent cancers. In our model, the SIYRYYGL antigen is expressed by cancer cells that lack the MHC-I molecule K needed for direct presentation, but the antigen is picked up and cross-presented by tumor stroma. A single injection of antigen-specific 2C CD8 T cells caused long-term inhibition of tumor growth, but without further intervention, tumors started to progress after approximately 3 months. Escape was associated with reduced numbers of circulating 2C cells. Tumor-infiltrating 2C cells produced significantly less TNFα and expressed more of the "exhaustion" markers PD-1 and Tim-3 than T cells from lymphoid organs. High-dose local ionizing radiation, depletion of myeloid-derived suppressor cells, infusions of additional 2C cells, and antibodies blocking PD-L1 did not prevent tumor escape. In contrast, adoptive transfer of allogeneic CD4 T cells restored the numbers of circulating Ag-specific CD8 T cells and their intratumoral function, resulting in tumor eradication. These CD4 T cells had no antitumor effects in the absence of CD8 T cells and recognized the alloantigen cross-presented on tumor stroma. CD4 T cells might also be effective in cancer patients when PD-1/PD-L1 blockade does not rescue intratumoral CD8 T-cell function and tumors persist. Cancer Immunol Res; 5(2); 127-36. ©2017 AACR.
过继转移的 CD8 T 细胞通过专门识别肿瘤基质中呈递的抗原,可在很长一段时间内稳定实体瘤的大小。然而,这些肿瘤最终会逃脱 T 细胞介导的生长控制。本研究旨在根除此类持续性癌症。在我们的模型中,SIYRYYGL 抗原由缺乏 MHC-I 分子 K 的癌细胞表达,该分子 K 是直接呈递所必需的,但该抗原被肿瘤基质摄取和交叉呈递。单次注射抗原特异性 2C CD8 T 细胞可长期抑制肿瘤生长,但如果没有进一步干预,肿瘤在大约 3 个月后开始进展。逃逸与循环 2C 细胞数量减少有关。肿瘤浸润的 2C 细胞产生的 TNFα 明显减少,并且表达的“耗竭”标志物 PD-1 和 Tim-3 比来自淋巴器官的 T 细胞更多。高剂量局部电离辐射、髓系来源的抑制细胞耗竭、额外 2C 细胞输注以及阻断 PD-L1 的抗体均不能预防肿瘤逃逸。相比之下,同种异体 CD4 T 细胞的过继转移可恢复循环 Ag 特异性 CD8 T 细胞的数量及其肿瘤内功能,从而导致肿瘤消除。这些 CD4 T 细胞在没有 CD8 T 细胞的情况下没有抗肿瘤作用,并且识别肿瘤基质中呈递的同种异体抗原。当 PD-1/PD-L1 阻断不能挽救肿瘤内 CD8 T 细胞功能且肿瘤持续存在时,CD4 T 细胞在癌症患者中也可能有效。Cancer Immunol Res; 5(2); 127-36. ©2017 AACR.